Tag
A shift from static portal pressure thresholds to dynamic, non-invasive risk prediction models offers improved prognostic accuracy for decompensation in advanced chronic liver disease, enabling personalized patient management and better cli
Carvedilol demonstrates superior effectiveness over nadolol and propranolol in reducing portal hypertension and preventing cirrhosis decompensation events, with emerging evidence supporting its preferential use in both compensated and decom
A prospective study reveals that decreased tryptophan levels in portal circulation induce neutrophil hyperactivation in alcoholic liver disease. In vitro supplementation with tryptophan ameliorated neutrophil activation, identifying the gut
The CIRROXABAN trial evaluates rivaroxaban’s efficacy and safety in preventing complications of portal hypertension in cirrhotic patients, suggesting improved complication-free survival without significantly increasing major bleeding
The CIRROXABAN trial evaluates rivaroxaban’s efficacy and safety in preventing complications of portal hypertension in cirrhotic patients, suggesting improved complication-free survival without significantly increasing major bleeding
